Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
BGENE GENETICS has 1 pending office action in Biotechnology & Pharmaceuticals. The matter is assigned to 1 distinct examiner and 1 distinct art unit, keeping the recorded prosecution activity concentrated. SWIFT, CANDICE LEE is the busiest examiner, with 1 pending matter.
The profile supports a targeted response centered on the office action handled by SWIFT, CANDICE LEE. Biotechnology & Pharmaceuticals identifies the technical setting for the examination, while the examiner and art-unit assignments show no recorded dispersion across the pending portfolio. The available data does not indicate additional matters requiring coordinated treatment.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SWIFT, CANDICE LEE | 1 | 56.5% | +38.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18577395 | Strain of Pseudomonas Putida Genetically Modified to Express a Benzalacetone Reductase | SWIFT, CANDICE LEE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18577395 | Strain of Pseudomonas Putida Genetically Modified to Express a Benzalacetone Reductase | SWIFT, CANDICE LEE | — |
| Art Unit | Apps |
|---|---|
| 1657 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18577395 | Strain of Pseudomonas Putida Genetically Modified to Express a Benzalacetone Reductase | SWIFT, CANDICE LEE | 1657 | §101§102§103§112Other | Final Rejection | — | Pending | Jan 08, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialBGENE GENETICS has 1 pending office actions as of November 2026, spread across 1 art units and 1 examiners.
Candice Lee Swift has the most, with 1 of BGENE GENETICS's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.